ライフサイエンスコーパス: cutaneous T-cell lymphoma

1 for the treatment of persistent or recurrent cutaneous T cell lymphoma.

2 developed for the treatment of patients with cutaneous T cell lymphoma.

3 ACs), was recently approved for treatment of cutaneous T cell lymphoma.

4 ention of solid tumors and are used to treat cutaneous T cell lymphoma.

5 kines may have added therapeutic benefit for cutaneous T cell lymphoma.

6 CCR4 in the blood and skin of patients with cutaneous T cell lymphoma.

7 often deficient on the malignant T cells of cutaneous T cell lymphoma.

8 ells derived from the blood of patients with cutaneous T cell lymphoma.

9 tors of anti-tumor cell-mediated immunity in cutaneous T cell lymphoma.

10 cells, that resulted in a pattern mimicking cutaneous T cell lymphoma.

11 for Hdac inhibitors that are efficacious in cutaneous T cell lymphoma.

12 ary syndrome are the most common subtypes of cutaneous T-cell lymphoma.

13 gets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma.

14 is fungoides (MF) is the most common primary cutaneous T-cell lymphoma.

15 ion for patients with relapsed or refractory cutaneous T-cell lymphoma.

16 is indicated for the treatment of refractory cutaneous T-cell lymphoma.

17 approved for the treatment of patients with cutaneous T-cell lymphoma.

18 Administration approved for the treatment of cutaneous T-cell lymphoma.

19 llenges in diagnosing and treating pediatric cutaneous T-cell lymphoma.

20 orms, and to recognize its relationship with cutaneous T-cell lymphoma.

21 ministration for vorinostat for treatment of cutaneous T-cell lymphoma.

22 approved for SAHA (vorinostat) treatment of cutaneous T-cell lymphoma.

23 from an international registry of pediatric cutaneous T-cell lymphoma.

24 ses in childhood: pityriasis lichenoides and cutaneous T-cell lymphoma.

25 presentation are characteristic of pediatric cutaneous T-cell lymphoma.

26 assess the safety and activity of IPH4102 in cutaneous T-cell lymphoma.

27 a, such as CD30+ Hodgkin's disease and CD30+ cutaneous T-cell lymphoma.

28 estrina with CD8(+) T-cell mycosis fungoides-cutaneous T-cell lymphoma.

29 ells in 3 patients with nodal involvement by cutaneous T-cell lymphoma.

30 pigtailed macaque (Macaca nemestrina) with a cutaneous T-cell lymphoma.

31 atopic and allergic contact dermatitis, and cutaneous T-cell lymphoma.

32 licating UV radiation in the pathogenesis of cutaneous T-cell lymphoma.

33 s, comprises the second most common group of cutaneous T-cell lymphoma.

34 c T-cell lymphoma and large-cell transformed cutaneous T-cell lymphoma.

35 fungoides (MF) is the most frequent form of cutaneous T-cell lymphoma.

36 es of mycosis fungoides, a common variant of cutaneous T-cell lymphoma.

37 n of EZH2 activity in large-cell transformed cutaneous T-cell lymphoma.

38 nal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma.

39 S) is an aggressive CD4+ leukemic variant of cutaneous T-cell lymphoma.

40 cancer prodrug approved for the treatment of cutaneous T-cell lymphoma.

41 ons of these agents to treat skin cancer and cutaneous T-cell lymphoma.

42 CpGs have demonstrated efficacy for cutaneous T-cell lymphoma.

43 diated itch, including atopic dermatitis and cutaneous T-cell lymphoma.

44 us cell cancer, lentigo maligna melanoma and cutaneous T-cell lymphoma.

45 of two HDAC inhibitors for the treatment of cutaneous T-cell lymphoma.

46 irst HDACi was approved for the treatment of cutaneous T cell lymphomas.

47 re few data on the molecular pathogenesis of cutaneous T cell lymphomas.

48 umulate in the skin, a diagnostic feature of cutaneous T cell lymphomas.

49 gression and may have applicability to human cutaneous T-cell lymphomas.

50 ve disease (PCLPD) is a spectrum of indolent cutaneous T-cell lymphomas.

51 d is a potential future treatment option for cutaneous T-cell lymphomas.

52 -delta 1 (TCR delta 1) expression in primary cutaneous T-cell lymphomas.

53 eviously treated patients with CD30-positive cutaneous T-cell lymphomas.

54 fungoides (MF), the most common subtypes of cutaneous T-cell lymphomas.

55 d to evaluate safety and efficacy in CD30(+) cutaneous T-cell lymphomas.

56 unoblastic T-cell lymphoma and other primary cutaneous T-cell lymphomas.

57 redominant Hodgkin's disease (7 cases), CD4+ cutaneous T-cell lymphomas (6 cases), adult T-cell leuke

58 e peripheral blood and skin of patients with cutaneous T cell lymphoma, a putative malignancy of the

59 Sezary syndrome is an advanced form of cutaneous T-cell lymphoma, a clonally derived malignancy

60 poses an intriguing model for miR therapy is cutaneous T-cell lymphoma, a rare disease featuring mali

61 n 56 of 111 (50%) samples from patients with cutaneous T-cell lymphoma, accounting for 7-18,155 cells

62 ymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphom

63 al role for HTLV-1 in these cases of primary cutaneous T-cell lymphoma after solid organ transplant.

64 otherapy demonstrated activity in refractory cutaneous T-cell lymphomas, along with acceptable toxici

65 thway may play a role in the pathogenesis of cutaneous T-cell lymphomas, although the mechanism (indu

66 lly confirmed relapsed or refractory primary cutaneous T-cell lymphoma, an Eastern Cooperative Oncolo

67 f malignant T cells from the skin lesions of cutaneous T cell lymphoma and the isolation of tumor-inf

68 .S. cases per year) that now exceeds that of cutaneous T-cell lymphoma and a mortality (33%) exceedin

69 (HDAC) inhibitors are currently approved for cutaneous T-cell lymphoma and are in mid-late stage tria

70 h2 phenotype in patients with advanced-stage cutaneous T-cell lymphoma and highlight the Gal-1-Gal-1

71 let A radiation, is used clinically to treat cutaneous T-cell lymphoma and immune-mediated diseases s

72 acetylase inhibitor used in the treatment of cutaneous T-cell lymphoma and in clinical trials for tre

73 It is approved for the treatment of cutaneous T-cell lymphoma and is used experimentally for

74 l cell and squamous cell cancers, as well as cutaneous T-cell lymphoma and lentigo maligna melanoma.

75 vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, wi

76 fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma and may rarely infiltrate the

77 urvival between the patients with alpha beta cutaneous T-cell lymphoma and patients with gamma delta

78 e deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia.

79 (SAHA), is currently being used for treating cutaneous T-cell lymphoma and under clinical trials for

80 nical trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and LyP from 2011 to 2013.

81 tyrosine kinase Brk in a large proportion of cutaneous T-cell lymphomas and other transformed T- and

82 hat cell-mediated responses are important in cutaneous T cell lymphoma, and that augmentation of thes

83 (SAHA) has been approved as a drug to treat cutaneous T cell lymphoma, and the combination of HDACi

84 nical treatment of several skin diseases and cutaneous T cell lymphoma, and they are also commonly us

85 levels as a tumor classification scheme for cutaneous T cell lymphomas, and have promise in the phar

86 gkin disease patients, non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and acute leukemias.

87 f aberrant cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft-versus-host disease

88 a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leuk

89 ed but dramatic response in one patient with cutaneous T-cell lymphoma, and prolongation of progressi

90 nodal peripheral T-cell lymphomas, 1/3 CD8+ cutaneous T-cell lymphomas, and 5/38 classical Hodgkin's

91 pityriasis versicolor, nummular eczema, and cutaneous T-cell lymphoma are important to consider in t

92 Cutaneous T-cell lymphomas are rare, generally incurable

93 Malignant melanoma and mycosis fungoides (cutaneous T cell lymphoma) are rare malignancies in chil

94 tic efficacy of this cytokine in early stage cutaneous T cell lymphoma as compared with more advanced

95 Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely if ever

96 been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymp

97 Sezary syndrome (SzS) is an advanced form of cutaneous T-cell lymphoma associated with involvement of

98 s (MF) is the most frequent manifestation of cutaneous T cell lymphoma but its cause and pathophysiol

99 Its efficacy has been shown in CD25+ cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin

100 ve demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action

101 kin biopsy specimens of 104 individuals with cutaneous T-cell lymphoma by immunohistochemistry.

102 from 42 patients with the leukemic phase of cutaneous T cell lymphoma (CD4/CD8 ratio of 10 or more w

103 In a cutaneous T-cell lymphoma cell line, promoter hypermethy

104 fects of enzastaurin on the viability of the cutaneous T-cell lymphoma cell lines HuT-78 and HH by us

105 e enhancer region, of the ICOS gene, whereas cutaneous T-cell lymphoma cell lines, which strongly exp

106 Sezary syndrome is a rare leukemic form of cutaneous T cell lymphoma characterized by generalized r

107 ezary syndrome (SS) is the leukemic phase of cutaneous T cell lymphoma characterized by the prolifera

108 Mycosis fungoides (MF) is a cutaneous T-cell lymphoma characterized by multifocal di

109 ome (SS) is an incurable leukemic variant of cutaneous T-cell lymphoma characterized by recurrent chr

110 is an aggressive leukemic variant of primary cutaneous T-cell lymphoma characterized by the presence

111 een associated with the development of human cutaneous T cell lymphomas, chronic lymphocytic leukemia

112 ecular mechanisms by which advanced cases of cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Seza

113 e to identify Vbeta+ cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the perc

114 ape and dynamics of active regulatory DNA in cutaneous T cell lymphoma (CTCL) by ATAC-seq.

115 In this article, we report that cutaneous T cell lymphoma (CTCL) cells and tissues ubiqu

116 Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lympho

117 We previously showed that within cutaneous T cell lymphoma (CTCL) lesions, malignant CD4(

118 yndrome is a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the mali

119 -10, is a hallmark of the advanced stages of cutaneous T cell lymphoma (CTCL), where it has been asso

120 ved for single-agent treatment of refractory cutaneous T cell lymphoma (CTCL).

121 ant mature CD4(+) T lymphocytes derived from cutaneous T cell lymphomas (CTCL) variably display some

122 is currently in phase II clinical trials for cutaneous T cell lymphomas (CTCL), but the mechanism of

123 st cells in skin biopsies from patients with cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell ly

124 ezary syndrome (SS) is a leukemic variant of cutaneous T-cell lymphoma (CTCL) and represents an ideal

125 Patients with cutaneous T-cell lymphoma (CTCL) are frequently colonize

126 Therapeutic options for cutaneous T-cell lymphoma (CTCL) are limited and curativ

127 (TL) and telomerase activity (TA) in primary cutaneous T-cell lymphoma (CTCL) by using quantitative p

128 FAS expression was generally low in 30 of 31 cutaneous T-cell lymphoma (CTCL) cases (mycosis fungoide

129 address the antitumor effect of curcumin on cutaneous T-cell lymphoma (CTCL) cell lines and peripher

130 nhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin i

131 s and Sezary syndrome are two major forms of cutaneous T-cell lymphoma (CTCL) characterized by resist

132 n 20 individuals with well-defined stages of cutaneous T-cell lymphoma (CTCL) comprising 10 cases wit

133 Cutaneous T-cell lymphoma (CTCL) constitutes a malignant

134 Studies in an in vitro model of cutaneous T-cell lymphoma (CTCL) demonstrated that CTCL

135 Cutaneous T-cell lymphoma (CTCL) encompasses leukemic va

136 Patients with advanced cutaneous T-cell lymphoma (CTCL) exhibit profound defect

137 orts in recent years, a curative therapy for cutaneous T-cell lymphoma (CTCL) has not yet been develo

138 y of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in t

139 ll lines and tissue samples of patients with cutaneous T-cell lymphoma (CTCL) have reported a detecti

140 Cutaneous T-cell lymphoma (CTCL) incidence and survival

141 of HTLV-I genetic sequences in patients with cutaneous T-cell lymphoma (CTCL) including mycosis fungo

142 Systemic treatment for cutaneous T-cell lymphoma (CTCL) involves the use of les

143 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous grou

144 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous grou

145 Cutaneous T-cell lymphoma (CTCL) is a heterogeneous non-

146 Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin

147 Cutaneous T-cell lymphoma (CTCL) is an aggressive neopla

148 Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hod

149 Progression of cutaneous T-cell lymphoma (CTCL) is associated with prof

150 Cutaneous T-cell lymphoma (CTCL) is characterized by pro

151 Cutaneous T-cell lymphoma (CTCL) is characterized by the

152 Cutaneous T-cell lymphoma (CTCL) is defined by infiltrat

153 Cutaneous T-cell lymphoma (CTCL) is typically a skin-inf

154 murine T-cell lymphoma line, MBL2, and human cutaneous T-cell lymphoma (CTCL) lines, HH and Hut78, we

155 Cutaneous T-cell lymphoma (CTCL) may present with eczema

156 Importance: Cutaneous T-cell lymphoma (CTCL) of the hands and feet c

157 Sezary syndrome (SS) is an aggressive cutaneous T-cell lymphoma (CTCL) of unknown etiology in

158 ropositivity increases with age, a subset of cutaneous T-cell lymphoma (CTCL) patients 55 years or yo

159 eripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinica

160 Advanced cutaneous T-cell lymphoma (CTCL) remains an unmet medica

161 ies, compared to six healthy control and six cutaneous T-cell lymphoma (CTCL) samples from previously

162 T-cell lines established from patients with cutaneous T-cell lymphoma (CTCL) spontaneously secrete I

163 ing cells and because malignant cells of the cutaneous T-cell lymphoma (CTCL) subset, Sezary syndrome

164 mycosis fungoides or Sezary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes.

165 Previous cytogenetic studies of primary cutaneous T-cell lymphoma (CTCL) were based on limited n

166 Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously rec

167 is fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL), a heterogeneous group

168 mpound 1 has FDA approval as a treatment for cutaneous T-cell lymphoma (CTCL), although treatment wit

169 roRNA (miRNA) dysregulation is a hallmark of cutaneous T-cell lymphoma (CTCL), an often-fatal maligna

170 n mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), as compared to normal

171 The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sezary syndr

172 d by the US Food and Drug Administration for cutaneous T-cell lymphoma (CTCL), including the leukemic

173 ts with stage IA to III, CD25 assay-positive cutaneous T-cell lymphoma (CTCL), including the mycosis

174 s of mycosis fungoides (MF), the most common cutaneous T-cell lymphoma (CTCL), is unknown.

175 In early-stage cutaneous T-cell lymphoma (CTCL), malignant T cells are

176 The pathogenesis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF)

177 initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fu

178 nction and histologically confirmed relapsed cutaneous T-cell lymphoma (CTCL), other non-Hodgkin's ly

179 immunotherapy on the natural progression of cutaneous T-cell lymphoma (CTCL), particularly the mycos

180 In the initial stage of cutaneous T-cell lymphoma (CTCL), proliferating CTCL cel

181 depsin in patients with treatment refractory cutaneous T-cell lymphoma (CTCL).

182 cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL).

183 vanced mycosis fungoides and Sezary syndrome cutaneous T-cell lymphoma (CTCL).

184 ave shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL).

185 tional properties of cells derived from CD4+ cutaneous T-cell lymphoma (CTCL).

186 in malignant CD4(+) T cells derived from the cutaneous T-cell lymphoma (CTCL).

187 Group classification and staging system for cutaneous T-cell lymphoma (CTCL).

188 tic progression in models of skin cancer and cutaneous T-cell lymphoma (CTCL).

189 ) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL).

190 (SS), the erythrodermic and leukemic form of cutaneous T-cell lymphoma (CTCL).

191 ber of hematological malignancies, including cutaneous T-cell lymphoma (CTCL).

192 e lesional skin of 42 American patients with cutaneous T-cell lymphoma (CTCL).

193 lase inhibitor approved for the treatment of cutaneous T-cell lymphoma (CTCL).

194 a 1 (PLCG1) is frequently mutated in primary cutaneous T-cell lymphoma (CTCL).

195 vival, proliferation, and tumor formation in cutaneous T-cell lymphoma (CTCL).

196 miR-150) repression in an aggressive form of cutaneous T-cell lymphoma (CTCL).

197 ttle is known about their pathogenic role in cutaneous T-cell lymphoma (CTCL).

198 CuV was further detected in a proportion of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides skin

199 diagnosis and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expre

200 Compound 1 is FDA-approved for treatment of cutaneous T-cell lymphoma (CTCL); however, 1 can provoke

201 Compound 1 has FDA approval to treat cutaneous T-cell lymphoma (CTCL); however, its use can c

202 Cutaneous T-cell lymphomas (CTCL) represent a spectrum o

203 tigate the anti-tumor effects of avicin D in cutaneous T-cell lymphomas (CTCL), we compared three CTC

204 (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL).

205 es of CCND1 and its regulator RB1 in primary cutaneous T-cell lymphomas (CTCL).

206 Cutaneous T cell lymphomas (CTCLs) are a heterogenous gr

207 Cutaneous T cell lymphomas (CTCLs) represent a heterogen

208 and Sezary syndrome comprise the majority of cutaneous T cell lymphomas (CTCLs), disorders notable fo

209 Cutaneous T-cell lymphomas (CTCLs) accounted for 71% (ag

210 Cutaneous T-cell lymphomas (CTCLs) are a family of prima

211 Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous g

212 Cutaneous T-cell lymphomas (CTCLs) are a heterogenous gr

213 Cutaneous T-cell lymphomas (CTCLs) are malignancies of T

214 Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lym

215 Advanced-stage cutaneous T-cell lymphomas (CTCLs) are notorious for the

216 Primary cutaneous T-cell lymphomas (CTCLs) encompass a wide vari

217 Cutaneous T-cell lymphomas (CTCLs) form a heterogeneous

218 Cutaneous T-cell lymphomas (CTCLs) primarily affect skin

219 Cutaneous T-cell lymphomas (CTCLs) represent a group of

220 n diftitox was approved for the treatment of cutaneous T-cell lymphomas (CTCLs) with CD25+ expression

221 ly driven diseases, the malignant T cells of cutaneous T-cell lymphomas (CTCLs), such as Sezary syndr

222 eviously been shown to be hypermethylated in cutaneous T-cell lymphomas (CTCLs), using standard bisul

223 common but aggressive subset of CD8(+) human cutaneous T-cell lymphomas (CTCLs).

224 Sezary syndrome, are the most common primary cutaneous T-cell lymphomas (CTCLs).

225 but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCLs).

226 likely to be most effective for early stage cutaneous T cell lymphoma due to a greater display of be

227 thyroxine concentrations) in a patient with cutaneous T-cell lymphoma during therapy with the retino

228 In a model of cutaneous T cell lymphoma, epidermotropic CD4(+) TRM lym

229 Two patients with cutaneous T-cell lymphoma experienced major antitumor re

230 er the neoplastic T cells from patients with cutaneous T-cell lymphoma express tumor-specific antigen

231 blood of a patient with an indolent form of cutaneous T-cell lymphoma, express wild-type TbetaRII an

232 eterogenous immune-mediated diseases such as cutaneous T cell lymphoma, graft-versus-host disease, an

233 tochemotherapy (ECP) is widely used to treat cutaneous T-cell lymphoma, graft-versus-host disease, an

234 e National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1

235 Four patients with advanced cutaneous T-cell lymphoma had CD8 cells that specificall

236 cell receptor junctional region sequences in cutaneous T-cell lymphoma had not been previously report

237 ls with recombinant human interleukin-12 for cutaneous T cell lymphoma have demonstrated that it is a

238 and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics t

239 l cancer kindred and a panel we designed for cutaneous T cell lymphoma in order to compare detection

240 Forty-two patients with cutaneous T-cell lymphoma, including 31 with exfoliative

241 CXCR4, and CCR10, in the pathophysiology of cutaneous T-cell lymphoma, including mycosis fungoides a

242 cles on pityriasis lichenoides and pediatric cutaneous T-cell lymphoma, including recent findings fro

243 Among the novel therapies for cutaneous T-cell lymphoma, interleukin-2 fusion toxins,

244 Cutaneous T cell lymphoma is a clonally derived, skin-in

245 Cutaneous T-cell lymphoma is a form of non-Hodgkin lymph

246 Cutaneous T-cell lymphoma is a heterogeneous group of ly

247 Cutaneous T-cell lymphoma is a rare but underrecognized

248 Cutaneous T-cell lymphoma is the overall name for a grou

249 Peripheral blood involvement by cutaneous T-cell lymphoma is typically assessed by flow

250 A distinctive clinical feature of cutaneous T-cell lymphomas is their sensitivity to treat

251 e Sezary form, or typically leukemic form of cutaneous T cell lymphoma, is characterized by prominent

252 ne receptors by tumors, specifically CCR4 on cutaneous T cell lymphomas, is often associated with a p

253 zary syndrome (SzS), the leukemic variant of cutaneous T-cell lymphomas, is incurable.

254 hydroxamic acid is already approved to treat cutaneous T-cell lymphoma, it could potentially be used

255 report, we show that patients with leukemic cutaneous T-cell lymphomas, known to have limited comple

256 A and CCR4 were also found at high levels in cutaneous T cell lymphoma lesions along with abundant ex

257 toxin efficiently eradicated CCR4-expressing cutaneous T cell lymphoma/leukemia established in NOD-SC

258 ed 17 adults with stage IA through stage IIA cutaneous T-cell lymphoma, MF type, to evaluate treatmen

259 onsiveness was assessed in 276 patients with cutaneous T cell lymphoma (mycosis fungoides and Sezary

260 ith early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type,

261 Although most patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are s

262 mycosis fungoides, and one (2%) had primary cutaneous T-cell lymphoma, not otherwise specified.

263 an extended survival, and the development of cutaneous T cell lymphomas of CD8(+)CD4(-) phenotype.

264 Seven partial responses were observed in cutaneous T-cell lymphoma (one patient), HCL (three pati

265 administered to 28 patients who had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma

266 -cell lymphoma and patients with gamma delta cutaneous T-cell lymphoma (P <.0001).

267 sis colorectal cancer panel and 22% with the cutaneous T cell lymphoma panel.

268 vity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sezar

269 e signaling pathway previously implicated in cutaneous T-cell lymphoma pathogenesis, JAK/STAT signali

270 The addition of interleukin-12 to cutaneous T cell lymphoma patient peripheral blood cells

271 both the natural killer cell activity of 15 cutaneous T cell lymphoma patients as well as T cell sur

272 ntly, studies of acute myeloid leukaemia and cutaneous T cell lymphoma patients have revealed importa

273 In the blood of cutaneous T cell lymphoma patients with peripheral blood

274 rleukin-12 receptor expression by T cells of cutaneous T cell lymphoma patients.

275 udies addressing the therapeutic efficacy in cutaneous T-cell lymphoma patients.

276 vestigation of mogamulizumab is warranted in cutaneous T-cell lymphoma patients.

277 tion of malignant T cells from patients with cutaneous T cell lymphoma, PBMC from normal individuals,

278 to isolate and characterize tumor-associated cutaneous T-cell lymphoma peptides.

279 r cells from patients with leukemic forms of cutaneous T cell lymphoma, primarily Sezary syndrome (SS

280 thological findings of the leukemic phase of cutaneous T-cell lymphoma, primarily Sezary syndrome (SS

281 The hallmark of cutaneous T-cell lymphoma progression is epigenetic dysr

282 Cutaneous T-cell lymphomas represent clinically and biol

283 ) was more frequent than CDKN2A (12%) in all cutaneous T-cell lymphoma stages using quantitative reve

284 The specific role of MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (

285 Global overall response by cutaneous T-cell lymphoma subtype was a secondary endpoi

286 e near complete apoptosis (94%) in malignant cutaneous T cell lymphoma T cells, whereas lower levels

287 HL) 1.42 (1.00, 2.02) and 3.18 (1.01, 9.97); cutaneous T-cell lymphoma (TCL) 4.10 (2.70, 6.23) and 10

288 genetic remissions in patients with advanced cutaneous T-cell lymphoma that is refractory to standard

289 of T cell lymphomas and all (eight of eight) cutaneous T-cell lymphoma tissues with a transformed, la

290 distinctive class I associated molecules on cutaneous T-cell lymphoma tumor cells suggests that infi

291 is fungoides (MF) is the most common primary cutaneous T-cell lymphoma variant and is closely related

292 In 2 of 3 organ recipients, a cutaneous T-cell lymphoma was diagnosed 2 and 3 years af

293 rtant T-cell specific chromatin organizer in cutaneous T-cell lymphoma, whereas its expression and fu

294 d Sezary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous gr

295 Hypothyroidism may develop in patients with cutaneous T-cell lymphoma who are treated with high-dose

296 aluated thyroid function in 27 patients with cutaneous T-cell lymphoma who were enrolled in trials of

297 ated 14 patients with relapsed or refractory cutaneous T-cell lymphoma with escalating doses of bexar

298 group of patients with refractory, advanced, cutaneous T-cell lymphoma with evidence for graft-versus

299 s and treatment approaches for patients with cutaneous T-cell lymphoma with special emphasis on mycos

300 ribe the chromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of r